Invitae Multi-Cancer Panel
Use
The Invitae Multi-Cancer Panel analyzes genes associated with adult-onset, non-syndromic cancer predisposition across major organ systems such as breast, gynecologic, gastrointestinal, endocrine, genitourinary, skin, and brain/nervous system. This test helps confirm clinical diagnoses, predict disease progression, facilitate early detection, inform family planning, and promote clinical trial enrollment for hereditary cancer predisposition.
Special Instructions
The test is designed specifically for heritable germline mutations and is not appropriate for somatic mutations in tumor tissue. Contact client services with any questions regarding specific limitations or needs.
Limitations
This test may not detect structural rearrangements or variants in sequence with complex architecture. It may not fully resolve mosaicism, phasing, or mapping ambiguity. Sequence changes in promoter, non-coding exons, and other non-coding regions are typically not covered.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3mL
Minimum Volume
Not provided
Container
purple-top EDTA tube (K2EDTA or K3EDTA)
Other tests from different labs that may be relevant